ir.syndax.comInvestors | Syndax Pharmaceuticals, Inc.
ir.syndax.com Profile
Ir.syndax.com is a subdomain of syndax.com, which was created on 2004-06-29,making it 20 years ago.
Description：The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial...
Discover ir.syndax.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.syndax.com Information
| HomePage size: 59.153 KB |
| Page Load Time: 0.561393 Seconds |
| Website IP Address: 23.208.37.53 |
ir.syndax.com Similar Website
| Maryland Real Estate Investors Association - Maryland Real Estate Investors Association |
| Investor Relations :: CNS Pharmaceuticals, Inc. (CNSP) |
| Western Midstream - Investors - Investors |
| Mirum Pharmaceuticals, Inc. - Investor Relations |
| Investors | Kidoz Inc. – Kidoz Inc. |
| OMNOVA Solutions - Investors - Investors |
| Investors :: Conatus Pharmaceuticals Inc. (CNAT) |
| Investors | Marathon Oil Corporation - Investors |
| Axalta Coating Systems - Investors - Investors Overview |
| Investors & Media | Ionis Pharmaceuticals, Inc. |
| Inovio Pharmaceuticals, Inc. - INVESTORS & MEDIA |
| Connected Investors | Connect With Real Estate Investors |
| Investors | Fusion Pharmaceuticals - Overview |
| Lifeline Pharmaceuticals, LLC’s Login Page | Lifeline Pharmaceuticals, LLC |
| Investors - Toromont Industries Ltd. - Investors |
ir.syndax.com PopUrls
| Investors | Syndax Pharmaceuticals, Inc. https://ir.syndax.com/ |
| Press Releases | Syndax Pharmaceuticals, Inc. https://ir.syndax.com/press-releases |
| 0000950170-23-022802 | 8-K | XBRL Viewer https://ir.syndax.com/node/11736/xbrl-viewer |
| 0001564590-22-023045 | 8-K | XBRL Viewer https://ir.syndax.com/node/11091/xbrl-viewer |
| 8-K | XBRL Viewer | Syndax Pharmaceuticals INC https://ir.syndax.com/node/11481/xbrl-viewer |
| 0000950170-23-022802 | 8-K | iXBRL Viewer https://ir.syndax.com/node/11736/ixbrl-viewer |
| 8-K | XBRL Viewer | Syndax Pharmaceuticals INC https://ir.syndax.com/node/10731/xbrl-viewer |
| 8-K | XBRL Viewer | Syndax Pharmaceuticals INC https://ir.syndax.com/node/12371/xbrl-viewer |
| 0001564590-20-051287 | 10-Q | XBRL Viewer https://ir.syndax.com/node/9926/xbrl-viewer |
| Events & Presentations | Syndax Pharmaceuticals, Inc. https://ir.syndax.com/events-presentations |
| Quarterly Results | Syndax Pharmaceuticals, Inc. https://ir.syndax.com/quarterly-results |
| Press Release Details - Syndax Pharmaceuticals, Inc. https://ir.syndax.com/news-releases/news-release-details/sndx-5613-granted-fda-fast-track-designation-treatment |
| Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 ... https://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-fourth-quarter-and-full-year-2023 |
| Press Release Details - Syndax Pharmaceuticals, Inc. https://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-third-quarter-2022-financial |
| Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and ... https://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-first-quarter-2024-financial |
ir.syndax.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1616174822" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Fri, 19 Mar 2021 17:27:02 GMT |
| Link: http://ir.syndax.com/; rel="shortlink", http://ir.syndax.com/; rel="canonical", http://ir.syndax.com/investor-relations; rel="alternate"; hreflang="en", http://ir.syndax.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Request-ID: v-51b2529c-88d8-11eb-93b0-a7a77a7807be |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 12448 |
| Cache-Control: public, max-age=0, s-maxage=2700 |
| Expires: Fri, 19 Mar 2021 17:27:03 GMT |
| Date: Fri, 19 Mar 2021 17:27:03 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
ir.syndax.com Meta Info
| charset="utf-8"/ |
| content="Syndax Pharmaceuticals, Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="http://ir.syndax.com/investor-relations" property="og:url"/ |
| content="Investors | Syndax Pharmaceuticals, Inc." property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
ir.syndax.com Ip Information
| Ip Country: United States |
| City Name: Philadelphia |
| Latitude: 39.9528 |
| Longitude: -75.1646 |
ir.syndax.com Html To Plain Text
BackLeadership Board of Directors Scientific Advisory Board Vision, Mission, and Values Pipeline Back Pipeline SNDX-5613 Axatilimab Entinostat Publications & Meeting Presentations Clinical Trials Back Clinical Trials SNDX-5613 Clinical Trials Axatilimab Clinical Trials Compassionate Use Patients & Caregivers Investors Contact Us Contact Us About Pipeline Clinical Trials Patients & Caregivers Investors Join Us Investors Investors Investor Relations Investors Press Releases Events & Presentations Corporate Governance Management Board of Directors Committee Composition Contact the Board Financial Information SEC Filings Annual Reports and Proxies Quarterly Results Key Ratios Stock Information Historic Stock Lookup Investment Calculator Analyst Coverage Ownership Profile FAQs Contact Us Investors Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA. : Day High: Day Low: Volume: Data Provided by Refinitiv. Minimum 15 minutes delayed. Intra 3 mo. 6 mo. 1 yr. Press Releases 03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update 03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 02.24.21 Syndax Announces Participation at Two Upcoming Investor Conferences 12.18.20 Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index View all press releases Events & Presentations 03.09.21 / 3:35 PM EST Barclays Global Healthcare Conference 03.08.21 / 4:30 PM EST Syndax Fourth Quarter 2020 Conference Call 03.03.21 / 11:40 AM EST Cowen 41st Annual Health Care Conference View all events & presentations Shareholder Tools Printed Materials Email Alerts RSS Print Share Search Facebook Google LinkedIn Twitter RSS © 2021 Syndax | Terms of Use | Privacy Policy | Site MapPipeline News Investors...
ir.syndax.com Whois
Domain Name: SYNDAX.COM Registry Domain ID: 123713098_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.register.com Registrar URL: http://www.register.com Updated Date: 2023-05-30T08:05:07Z Creation Date: 2004-06-29T16:20:00Z Registry Expiry Date: 2024-06-29T16:20:00Z Registrar: Register.com, Inc. Registrar IANA ID: 9 Registrar Abuse Contact Email: domain.operations@web.com Registrar Abuse Contact Phone: +1.8777228662 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NICK.NS.CLOUDFLARE.COM Name Server: TANI.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T21:31:56Z <<<